Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health reports developments across a multinational biopharmaceutical and diagnostics business. Recurring updates cover operating results, financial guidance, BioReference laboratory testing services and digital access through BioReference Direct, and RAYALDEE commercialization through EirGen Pharma in Greater China.
The company also reports research collaborations and clinical development from ModeX Therapeutics, including its MSTAR multispecific antibody platform, MDX2301 for COVID-19 prevention, and MDX2003, a tetraspecific T-cell engager for B-cell lymphomas. News also includes pharmaceutical partnerships, diagnostic-service changes, investor presentations, and business updates tied to OPKO's pharmaceutical and diagnostics segments.
OPKO Health (NASDAQ: OPK) and Entera Bio (NASDAQ: ENTX) expanded their collaboration to advance a first-in-class oral long-acting PTH (LA-PTH) once-daily tablet for hypoparathyroidism. The program is 50/50 owned and cost-shared, with an IND filing targeted for late 2026 after favorable PK/PD preclinical data.
The companies maintain a 60/40 ownership and cost split (OPKO/Entera) for the oral oxyntomodulin (OXM) program, with injectable Phase 1 data expected by late 2026. Steve Rubin joins Entera's board as Gerry Ostrov steps down.
OPKO Health (Nasdaq: OPK) said its management team will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, held January 12-15, 2026. Management will host one-on-one investor meetings and take part in a fireside chat on Wednesday, January 14, 2026 at 1:30 p.m. PT. The fireside chat will be webcast live and available for replay in the Investors section of OPKO Health's website.
OPKO Health (Nasdaq: OPK) will participate in the Piper Sandler 37th Annual Healthcare Conference in New York City from December 2–4, 2025. Management will hold one-on-one investor meetings and appear in a fireside discussion on December 3, 2025 at 12:00 p.m. ET. Investors who want meetings are instructed to contact their Piper Sandler representative to schedule.
OPKO Health (NASDAQ: OPK) reported third-quarter 2025 results and business highlights on October 29, 2025, including a multi‑program research collaboration with Regeneron using ModeX MSTAR, with potential program milestones >$200M each and overall collaboration value potentially exceeding $1 billion. OPKO completed the sale of BioReference oncology assets to Labcorp for $225 million (including up to $32.5M earnout) and received $173.3M cash at closing. Consolidated Q3 revenue was $151.7M (down from $173.6M); operating income was $48.1M; net income was $21.6M ($0.03 diluted) which included a $101.6M gain on the asset sale. Cash and equivalents were $428.9M; $73.8M of share repurchases completed, $126.2M remaining.
ModeX Therapeutics (NASDAQ: OPK) announced a license and collaboration with Regeneron (NASDAQ: REGN) to discover and develop multispecific antibodies using ModeX’s MSTAR platform and Regeneron’s proprietary binders.
Key terms: an upfront payment of $7 million, per-molecule product selection, clinical and commercial milestone payments exceeding $200 million per selected molecule, tiered global net sales royalties up to the low double digits, and an overall collaboration value that potentially exceeds $1 billion if multiple products advance. Regeneron will fund and lead preclinical, clinical development and commercialization for products it advances. Targeted indications include immunology, oncology and metabolic diseases.
ModeX Therapeutics (NASDAQ: OPK) announced dosing of the first patient in a Phase 1/2a clinical trial (NCT07110584) of MDX2004, a first-in-class trispecific antibody-fusion protein designed as a T cell "rejuvenator."
MDX2004 engages CD3, CD28 and binds 4-1BB as a ligand to stimulate stem and memory T cells; the trial will evaluate safety, tolerability and biologic activity in advanced cancers. Two MDX2004 posters are scheduled at the SITC Annual Meeting, Nov 5-9, 2025.
OPKO Health (NASDAQ: OPK) will report operating and financial results for the three and nine months ended September 30, 2025 after U.S. market close on Wednesday, October 29, 2025.
Senior management will give a business update and discuss results and financial guidance on a conference call and live audio webcast starting at 4:30 p.m. Eastern on October 29. OPKO encourages pre-registration to receive a unique PIN for immediate access; dial-in options are 833-630-0584 (U.S.) and 412-317-1815 (International). A telephone replay is available until November 5, 2025 (passcode 8678248), and a webcast replay will be posted about one hour after the live call.
Labcorp (NYSE: LH) has completed the acquisition of select oncology and clinical testing assets from BioReference Health, a subsidiary of OPKO Health (Nasdaq: OPK). The transaction is valued at up to $225 million, comprising $192.5 million paid at closing and a potential $32.5 million performance-based earnout.
The acquisition strengthens Labcorp's oncology testing portfolio and expands its diagnostic capabilities. BioReference Health will retain its core clinical testing operations in NY/NJ and its 4Kscore® Test franchise, which generated approximately $300 million in revenue for 2024. OPKO plans to use part of the proceeds to fund its expanded share repurchase program.
OPKO Health (NASDAQ: OPK) reported Q2 2025 financial results with total revenues of $156.8 million, down from $182.2 million in Q2 2024. The company posted a net loss of $148.4 million ($0.19 per share), including a $91.7 million non-recurring expense related to convertible note exchange.
Key developments include Merck's advancement of Phase 1 Epstein-Barr virus vaccine trial, ModeX's progress in immuno-oncology portfolio, and promising preclinical data for OPK-88006 in diabetes treatment. The FDA approved a supplemental application for the 4KScore® Test, and the Board authorized an additional $100 million for stock repurchase, bringing total capacity to $200 million.
The Pharmaceuticals segment generated $40.7 million in product revenue, while Diagnostics revenue was $101.1 million. Cash position stood at $285.4 million as of June 30, 2025.
OPKO Health (NASDAQ:OPK) has scheduled its Second Quarter 2025 financial results announcement for July 31, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss operating and financial results for the three and six months ended June 30, 2025.
Participants can pre-register for the call through a provided link, or join by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A replay will be available until August 7, 2025, accessible via phone or webcast.